HemCon teams up with Irish institute for antibacterial technology
This article was originally published in Clinica
HemCon has licensed exclusive global rights from the Institute of Technology Sligo, Ireland, for its controlled-release hydrogen peroxide technology. Portland, Oregon-based HemCon plans to research, develop, manufacture and market the technology, which has broad-spectrum antibacterial and antiseptic properties. It can be used in wound and oral care, and has shown promise in early studies of fungal nail infection, which HemCon says has a global market of around $4bn.